Your session is about to expire
← Back to Search
Alcohol Dehydrogenase Inhibitor
Disulfiram for Coronavirus (DISCO Trial)
Phase 2
Waitlist Available
Led By Sulggi A Lee, MD PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0 and day 31
Awards & highlights
Summary
This trial is testing Disulfiram, a drug used to treat alcohol dependence, to see if it can help people with mild to moderate COVID-19. The drug might work by stopping the virus and reducing inflammation. Disulfiram is an approved oral drug used to treat alcohol use disorder and has shown potential in reducing the incidence and severity of COVID-19.
Eligible Conditions
- Coronavirus
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 0 and day 31
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 and day 31
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Immunologic Impact of 5 Days of Disulfiram, as Measured by the Fold-change in Plasma Levels of Pro-inflammatory Cytokines (e.g, Interleukin 6, Interleukin 1-beta, Etc.).
Secondary outcome measures
Change in COVID-19 Symptom Severity Score as Assessed by a 5-point Adapted Somatic Symptom Severity Score (SSS-8)
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
Virologic Impact of 5 Days of Disulfiram, as Measured by the Change in Copies of SARS-CoV-2 Virus Per mL Between Baseline and Day 31.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: DisulfiramExperimental Treatment1 Intervention
This study will provide disulfiram. Participants in Cohort 1 receiving disulfiram will take 2 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of disulfiram (each capsule contains 500 mg DSF plus 27.75 mg microcrystalline cellulose powder) per day for a total of 5 consecutive days.
Group II: PlaceboPlacebo Group1 Intervention
This study will provide placebo comparator for disulfiram. Participants in Cohort 1 receiving placebo will take 2 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days. Participants in Cohort 2 receiving placebo will take 4 capsules of placebo (each capsule contains only microcrystalline cellulose powder) per day for a total of 5 consecutive days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Disulfiram
2008
Completed Phase 4
~1300
Find a Location
Who is running the clinical trial?
University of California, San FranciscoLead Sponsor
2,528 Previous Clinical Trials
15,242,621 Total Patients Enrolled
Sulggi A Lee, MD PhDPrincipal InvestigatorUniversity of California, San Francisco
2 Previous Clinical Trials
19 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger